On July 16, 2026, Kalshi and AppliedXL launched the first regulated prediction markets on clinical trial outcomes and FDA drug approval decisions — 13 contracts covering some of the most closely watched drug programs in medicine.
For decades, the probability that a specific drug would succeed was locked inside private research firms, hedge funds, and pharmaceutical boardrooms. These contracts create a publicly visible, continuously updated probability on named FDA decisions and late-stage trial endpoints — anyone can see and trade the same number.
13
Contracts at launch
AppliedXL
Oracle partner
CFTC DCM
Regulatory status
Phase 3 only
Phase requirement
Every contract is anchored to a named public document whose reading criteria are locked before trading begins. AppliedXL — the independent resolution-analysis partner — defines exactly how that document will be read. Kalshi retains sole and final authority over every market outcome under its exchange rules.
The registered primary outcome the trial was designed to measure — agreed upon and publicly filed before results arrive. Prevents any post-hoc dispute about what the trial 'really showed.'
For regulatory-decision contracts: the official FDA approval or complete-response letter. The resolution source is named in the contract before trading opens.
When the FDA's expert panel vote determines the regulatory outcome, the advisory committee voting record is the contract's resolution anchor.
Source: Kalshi official announcement, July 16, 2026 · AppliedXL official announcement
The Phase 3 restriction addresses two risks simultaneously: early-phase endpoints are exploratory (harder to resolve objectively), and enrollment-open contracts could theoretically influence physician referral patterns and patient recruitment.
The biomedical context raised immediate concerns about insider trading. The pilot addresses three specific risk vectors.
An extra layer beyond standard account verification. Anyone who works at a company with material nonpublic information (MNPI) about a listed trial is explicitly prohibited from trading those contracts.
Phase 3 / late-stage only; enrollment must be closed before market opens
AppliedXL defines how the source document will be read before any market opens. A trial sponsor's favorable press-release framing cannot change the resolution outcome — the contract resolves on the registered primary endpoint, not the company's characterization.
Whether these safeguards are sufficient is an open question. Independent researchers have noted that financial incentives attached to trial outcomes could have downstream effects on reporting behavior — particularly selective reporting of secondary endpoints or timing of result publications.
Pharmaceutical development has a structural information problem. Private banks, expert networks, and pharmaceutical companies all produce probability estimates on trial outcomes — but those estimates stay behind closed doors. The rest of the world operates on incomplete public data.
A publicly listed contract produces a continuously updated probability that reflects the weight of available evidence, not the preferred messaging of the trial sponsor. Investors, smaller developers, clinicians, and patients can read the same number.
As of April 2026, the FDA reported that 29.6% of studies it considered highly likely subject to mandatory reporting requirements had no results information submitted to ClinicalTrials.gov. A continuously traded market price creates independent pressure for information to reach public markets. (Source: FDA data cited in the AppliedXL partnership announcement )
Drug stocks are blunt instruments. Owning a biotech stock means owning exposure to management quality, cash runway, macro conditions, and dozens of other pipeline drugs simultaneously. A clinical trial contract prices only one question.
Practically, the contracts offer two distinct uses:
Kalshi and AppliedXL published a joint whitepaper — Biopharma's Public Probability: The State and Future of Prediction Markets in Drug Development — examining the information these markets can produce, the risks they raise, and the standards required for them to function responsibly.
Kalshi Platform Review
Full review: fees, regulations, state availability, and market depth.
How Prediction Markets Resolve
Settlement mechanics, oracle sources, and resolution disputes explained.
Can Prediction Markets Be Manipulated?
What market manipulation looks like, who it affects, and how exchanges respond.
